Iomics Biosciences, a specialist in precision diagnostics, will promote the translation of omics-based technology into scientific research and R&D of new drugs with the fresh proceeds.
Recently Iomic Biosciences (Chinese: 格物致和) announced its completion of a Series A financing round worth nearly CNY 100 million (USD 15 million).
This round was led by Oriza Holdings（Chinese: 元禾原点） and Apricot Capital（Chinese: 杏泽资本). Potential Capita(Chinese: 取势资本）acted as the exclusive financial advisor.
The proceeds will be used to continuously develop its proprietary technology platform of the proteomics and space omics and accelerate the development and registration of its proprietary next-generation hypersensitive single molecule protein detection system and related neurodegenerative marker detection kit.
Iomics Biosciences, founded in 2019, is a biotech firm focusing on the early screening and detection of neurological diseases and cancers. Xu Junquan, the founder of Iomics Biosciences with 50 Intelligent Properties, has more than 20 years research and industry working experience in the field of in vitro diagnostics. He previously served as the general manager, COO and CFO of Bobao Biological Goup and CEO of Shenzhen Microchip Biotechnology.
Companies which also has a focus on protemics-based diagnostics include Nanomics (Chinese: 珞米生命科技) and Royal Advance (Chinese: 御领生物科技) and Applied Protein Technology (Chinese: 中科新生命).